ProfileGDS5678 / 1450093_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 67% 67% 65% 67% 68% 70% 68% 66% 66% 67% 71% 66% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9386865
GSM967853U87-EV human glioblastoma xenograft - Control 24.0871167
GSM967854U87-EV human glioblastoma xenograft - Control 34.0375967
GSM967855U87-EV human glioblastoma xenograft - Control 43.9137565
GSM967856U87-EV human glioblastoma xenograft - Control 54.0038467
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2099168
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3853170
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1795968
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0186466
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0266766
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.0880667
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4689771
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.0119266
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2051969